secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2024-09-24T23:59:59+00:00
Accession:  0001558370-24-012983
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor Therapeutics to file BLA for deramiocel in DMD cardiomyopathy; rolling submission in Oct 2024
--------------------------------------------------------------------------------

- Plans to file BLA for deramiocel to treat DMD cardiomyopathy based on existing cardiac and natural history data; rolling submission begins Oct 2024 with full submission by year-end 2024.
- BLA supported by Phase 2 HOPE-2 and HOPE-2 OLE data vs natural history from Vanderbilt and Cincinnati Children's.
- Will combine Cohorts A and B of Phase 3 HOPE-3 as a post-approval study; no unblinding of Cohort A as previously planned for Q4 2024.
- Deramiocel has FDA Orphan Drug, RMAT, and Rare Pediatric Disease designations (PRV eligible upon approval).
- No approved therapies for DMD cardiomyopathy; deramiocel targets leading cause of death in Duchenne.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837024012983/0001558370-24-012983-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837024012983/capr-20240924x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-012983

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer